MarketBeat
05 Nov 2026, 05:35 UTC · 13h ago
What Precigen (PGEN) Said on Its Q3 Earnings Call
Impact · against what's priced in
Precigen (PGEN) shows significant commercial momentum with rapid sales growth and unexpected profitability, removing immediate dilution risks. While the entry of an Inovio (INO) competitor in early 2027 introduces a growth cap, PGEN's established reimbursement and market lead provide a defensive buffer.
- PGEN+0.70
No priced-in read yet
- In context
Quarterly sales jumped from $21.5M to $72.9M over three quarters, with the company achieving a $35.8M net income in Q3 and positive operating cash flow of $11.9M, eliminating the immediate need for capital raises.
Read from the article alone
